MedTrace Logo

Gut Microbiota and Immune Recovery

NCT03478540 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2018-03-27

No results posted yet for this study

Summary

To explore whether gut microbiota would impact CD4 T cells recovery in HIV-infected patients on antiretroviral therapy (ART). We prospectively enroll patients initiate ART and collect their fecal at followup for one year.

Conditions

Interventions

DRUG

Anti-Retroviral Agents

First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz

Sponsors & Collaborators

  • Shanghai Public Health Clinical Center

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2019-05-30
Completion
2019-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03478540 on ClinicalTrials.gov